The functional variant RS334558 of GSK3B is associated with remission in patients with depressive disorders

Anastasia Levchenko, Innokentiy S. Losenkov, Natalia M. Vyalova, German G. Simutkin, Nikolay A. Bokhan, Bob Wilffert, Anton J.M. Loonen, Svetlana A. Ivanova

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: GSK3B and AKT1 genes have been implicated in the pathogenesis of a number of psychiatric and neurological disorders. Furthermore, their genetic variants are associated with response to antidepressant pharmacotherapy. As the evidence is still incomplete and inconsistent, continuing efforts to investigate the role of these two genes in the pathogenesis and treatment of brain disorders is necessary. The aim of our study was thus to evaluate the association of variants of these two genes with depressive disorders and drug treatment response. Patients and methods: In the present study, 222 patients with a depressive disorder who underwent pharmacological antidepressant treatment were divided into remitters and non-remitters following a 28-day course of pharmacotherapy. The association of a depressive disorder and remission rates with polymorphisms rs334558 in the GSK3B gene and rs1130214 and rs3730358 in the AKT1 gene was evaluated with a chi-square test. Results: Neither of the studied genetic variants was associated with a depressive disorder. Furthermore, frequencies of alleles and genotypes for rs1130214 and rs3730358 were not different in the groups of remitters and non-remitters. However, the activating allele T of the functional polymorphism rs334558 was significantly associated with remission, when all types of antidepressant drugs were included. This association continued as a trend when only patients taking selective serotonin reuptake inhibitors were considered. Conclusion: The present study provides support that the functional polymorphism rs334558 of GSK3B may play a role as a useful genetic and pharmacogenetic biomarker in the framework of personalized medicine approach.

Original languageEnglish
Pages (from-to)121-126
Number of pages6
JournalPharmacogenomics and Personalized Medicine
Volume11
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • AKT1
  • Association study
  • Depressive disorder
  • Genetic biomarker
  • GSK3B

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'The functional variant RS334558 of GSK3B is associated with remission in patients with depressive disorders'. Together they form a unique fingerprint.

  • Cite this

    Levchenko, A., Losenkov, I. S., Vyalova, N. M., Simutkin, G. G., Bokhan, N. A., Wilffert, B., Loonen, A. J. M., & Ivanova, S. A. (2018). The functional variant RS334558 of GSK3B is associated with remission in patients with depressive disorders. Pharmacogenomics and Personalized Medicine, 11, 121-126. https://doi.org/10.2147/PGPM.S171423